GSK bonuses cut by China bribery investigation
GlaxoSmithKline has cut the bonus of its chief executive Andrew Witty following China’s bribery investigation of the pharmaceutical company. In its 2013 annual report, the company said: “The ongoing investigation by authorities in China was also considered by the committee.
To read more
Subscribe to Global Investigations Review
Subscribe and start reading now
Global Investigations Review (GIR) is the hub for global coverage of corporate investigations and their aftermath. Keep up to date with significant developments in the corporate investigations world.